EQS-AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...

The best-performing unit trusts have exposure to US tech stocks, while the laggards were invested in commodities and ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

Industry Dominated by Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Merck KGaA, BD (Becton, Dickinson and ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Republicans and Democrats joined together to roll out a legislative package focused on increasing access to benefits to more ...

A Code Blue emergency declaration adds another layer of urgency to the work being done by homeless outreach groups throughout ...

After years of lending and investing in South Florida, Michael Dell’s BDT & MSD Partners is now looking to get into ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.